BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June

Day

• 1
• 2
• 5
• 6
• 7
• 8
• 9
• 12
• 13
• 14
• 15
• 16
• 19
• 20
• 21
• 22
• 23
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Layoffs

  Lexeo Trims 15% of Workforce, Shifts Focus to Lead Cardiac Programs

  Lexeo wants to more quickly move investigational gene therapy LX2006 into a registrational study and hopes for a potential efficacy readout in 2027.

  May 12, 2025

   · 

  1 min read

   · 

  Angela Gabriel
• 

  Obesity

  Lilly’s Zepbound Secures “Superior Benefit-Risk Ratio” Over Novo’s Wegovy

  In addition to eliciting greater weight loss than Novo Nordisk’s Wegovy, Eli Lilly’s Zepbound does not come at the expense of safety, according to newly released comprehensive tolerability data—findings that Leerink analysts say confirm the GLP-1 drug’s edge in the closely watched market race.

  May 12, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug pricing

  White House Unwraps Massive Drug Pricing Policy, Touching All Corners of Pharma

  The package revives President Donald Trump’s much-maligned Most Favored Nation rule but goes further into the private markets and beyond, leveraging the patent system, drug importation and more.

  May 12, 2025

   · 

  6 min read

   · 

  Annalee Armstrong
• 

  Drug pricing

  Trump’s Drug Pricing Order ‘More Bark Than Bite’

  While industry groups decried the Trump administration’s new drug pricing order, analysts say it lacked details and the teeth to make a major impact without an act of Congress.

  May 12, 2025

   · 

  5 min read

   · 

  Annalee Armstrong
• 

  Manufacturing

  Roche Makes $300M China Production Promise After Multibillion US Investment

  Last month, Roche committed $50 billion in U.S. manufacturing funds, with which it will construct at least four new facilities.

  May 12, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  PARTNERED

  Where AI Adds Real Value in Clinical Development

  While Quantum computing has been reported to be five years away for many years now, companies are preparing for it by setting foundations with AI in development.

  May 12, 2025

   · 

  7 min read

   · 

  BioSpace Insights
• 

  Infectious disease

  Biopharma Targets an HIV Cure as NIH Funding Cuts Threaten To Derail Progress

  As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are targeting the next goalpost: a cure.

  May 12, 2025

   · 

  7 min read

   · 

  Heather McKenzie
• 

  Radiopharmaceuticals

  Radiopharma Powerhouses Push Frontiers With New Indications, Innovation

  At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a radiopharmaceuticals market that could top $16 billion by 2033.

  May 12, 2025

   · 

  9 min read

   · 

  Tristan Manalac
• 

  Opinion

  Bringing Neurological Disease Into the Age of Precision Medicine

  To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of protein aggregates in the brain.

  May 12, 2025

   · 

  5 min read

   · 

  John McDonough
• 

  Vaccines

  FDA, EU Flag Safety Issues With Valneva’s Chikungunya Vaccine

  The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ongoing.

  May 12, 2025

   · 

  2 min read

   · 

  Tristan Manalac